Companies / BIT

BIOTRON LIMITED

ASX:BITPharmaceuticals, Biotechnology & Life Sciences
2.79B shares on issueASX (delayed) · as of 28 July 2026$0.002price · delayed$5.6Mmarket cap · indicative
F
Dilution grade

Runway under 2 quarters; share count grew 209% in 24 months; 3 cash raises in 24 months

Cash runway1.8 quarters of funding
Share-count growth (24m)208.7%
Raise cadence (24m)3 cash raises
Options & rights overhang26.0% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

BIOTRON LIMITED's ordinary share count grew 208.7% between July 2024 and July 2026, to 2.79B shares. The company raised capital three times in that period for total disclosed proceeds of A$6.3M, most recently a A$2.5M placement and rights issue in October 2025. Options and rights on issue could convert into 725M new shares, equal to 26.0% of the current share count, with 0% of current shares in the money and the nearest expiry in November 2027. At the June 2026 quarter the company reported A$1.3M in available cash, about 1.8 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
26.0%
Max option dilution
0.0%
ITM option dilution
2
Raises · last 12 months
1.8 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 2.79B per ASX (delayed) (28 July 2026).
1.30B1.84B2.39BDec 24Sept 25July 26Cash raise · 17 Oct 2025Cash raise · 10 Oct 2025Cash raise · 27 Feb 2025

Cash runway

1.8 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$1.3M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
13 July 20262A · quoted issueBIT : ORDINARY FULLY PAID2.79BAppendix 2A
17 June 20262A · quoted issueBIT : ORDINARY FULLY PAID2.70BAppendix 2A
29 Jan 20262A · quoted issueBIT : ORDINARY FULLY PAID2.70BAppendix 2A
23 Dec 20252A · quoted issueBIT : ORDINARY FULLY PAID2.41BAppendix 2A
23 Dec 20253G · unquotedBIT : ORDINARY FULLY PAID2.41BAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

3 cash raises in the last 24 months · 2 in the last 12 months

$2.5M
Placement and Rights Issue
17 Oct 2025 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

26.0%
Total overhang · of current shares
0.0%
In the money · at current price
725.2M
Potential new shares
Nov 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
13 July 2026Paul KasianBuy12.2M——3Y notice
13 July 2026Graeme WaldBuy16.3M——3Y notice
19 Dec 2025Robert B. ThomasBuy2.8M1.4M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

21 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
15 July 2026Change of Director's Interest Notice
13 July 2026Application for quotation of securities - BIT
13 July 2026$PSedarex First Milestone Met
17 June 2026Application for quotation of securities - BIT
3 June 2026$P$525K R&D Rebate Received
29 May 2026Release From Voluntary Escrow
15 May 2026Final Director's Interest Notice
29 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
9 Apr 2026Director Retirement
30 Mar 2026Director Appointment Graeme Wald & Appendix 3X
19 Mar 2026Investor Update
17 Mar 2026$PHepatitis B Virus Program Update
26 Feb 2026$PHalf Yearly Report and Accounts
6 Feb 2026Final Director's Interest Notice
29 Jan 2026Supplementary Prospectus
29 Jan 2026Application for quotation of securities - BIT
29 Jan 2026$PSuccessful Issue of the Entitlement Offer Shortfall
28 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
12 Jan 2026Becoming a substantial holder

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.